News | 21 November 2025
Alkem launches globally acclaimed De Simone Probiotic in India, expands GI portfolio
The formulation is backed by over 80 clinical trials and 200 scientific publications
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The move is expected to be crucial during health crises
.png)
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Consolidated revenue from operations stood at Rs. 111.05 crore
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
Subscribe To Our Newsletter & Stay Updated
